Endometriosis Trial, Recruiting NCT07393958 Sponsor: Arafarma Group, S.A. Condition: Endometriosis
Back to Endometriosis

Endometriosis Trial, Recruiting

NCT07393958
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman of childbearing age who has been diagnosed with endometriosis at stage I, II, or III (according to a standard medical classification system).
  • Your endometriosis has been confirmed by keyhole surgery (laparoscopy), or if that has not been done, by an MRI scan and/or ultrasound.
  • You have been experiencing pelvic pain rated above 4 out of 10 on a pain scale during the last three months.
  • At the time of joining the study, doctors do not currently recommend surgery for your condition.
  • You are able to understand and sign a consent form agreeing to take part in the study.

Who may not be able to join:

  • You are under 18 years of age.
  • You are taking pain relief or anti-inflammatory medications, except for ibuprofen up to 600 mg per day or naproxen up to 500 mg per day.
  • You had surgery related to your endometriosis within the year before joining the study.
  • You started or stopped hormone therapy (such as hormonal contraceptives or other hormone treatments) within the three months before joining the study.
  • You have a known allergy or sensitivity to a medication called Doliral®.
  • You are currently pregnant or breastfeeding.
  • You have been off work due to illness for more than one year, have no plans to return to work, or are currently going through a formal assessment for disability or long-term incapacity.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: TAMARA RODRIGUEZ ARAYA, Dr, Hospital Clinic of Barcelona

Phone: +34 932 27 54 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Arafarma Group, S.A.
Registry
ClinicalTrials.gov
Start date
26 February 2026
Est. completion
1 August 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

To measure the improvement of the quality of life.; To measure the improvement of the quality of life.; To measure the improvement of the quality of life.; To measure the improvement in pain intensity.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov